Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib

BACKGROUND. A phase III trial compared lapatinib plus letrozole (L + Let) with letrozole plus placebo (Let) as first-line therapy for hormone receptor (HR)(+) metastatic breast cancer (MBC) patients. The primary endpoint of progression-free survival (PFS) in patients whose tumors were human epiderma...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Sherrill, Beth, Amonkar, Mayur M., Sherif, Bintu, Maltzman, Julie, O'Rourke, Lisa, Johnston, Stephen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2010
Konular:
Academia–Pharma Intersect
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228031/
https://ncbi.nlm.nih.gov/pubmed/20798196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0012
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller